[go: up one dir, main page]

NO20044954L - Bazedoxifen behandlingsregimer - Google Patents

Bazedoxifen behandlingsregimer

Info

Publication number
NO20044954L
NO20044954L NO20044954A NO20044954A NO20044954L NO 20044954 L NO20044954 L NO 20044954L NO 20044954 A NO20044954 A NO 20044954A NO 20044954 A NO20044954 A NO 20044954A NO 20044954 L NO20044954 L NO 20044954L
Authority
NO
Norway
Prior art keywords
bazedoxifene
treatment regimens
azepan
indol
hydroxyphenyl
Prior art date
Application number
NO20044954A
Other languages
English (en)
Inventor
Barry Samuel Komm
Mark A Collins
Wendy Ann Dulin
James C Ermer
Geraldine M Ferron
Pol Boudes
Simon N Jenkins
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20044954L publication Critical patent/NO20044954L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Denne oppfinnelse angår utvidede doseringsregimer for den selektive østrogenreseptormodulator bazedoxifen (1 -[4-(2-azepan-1-yl-etoksy)-benzyl]-2-(4-hydroksyfenyl)-3-metyl-1H-indol-5-ol).
NO20044954A 2002-06-13 2004-11-12 Bazedoxifen behandlingsregimer NO20044954L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38859602P 2002-06-13 2002-06-13
PCT/US2003/019011 WO2003105834A1 (en) 2002-06-13 2003-06-13 Bazedoxifene treatment regimens

Publications (1)

Publication Number Publication Date
NO20044954L true NO20044954L (no) 2004-12-16

Family

ID=29736501

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044954A NO20044954L (no) 2002-06-13 2004-11-12 Bazedoxifen behandlingsregimer

Country Status (20)

Country Link
US (1) US20040063692A1 (no)
EP (1) EP1531807A4 (no)
JP (1) JP2005531613A (no)
KR (1) KR20050010886A (no)
CN (1) CN1658868A (no)
AU (1) AU2003248707A1 (no)
BR (1) BR0311774A (no)
CA (1) CA2489098A1 (no)
CR (1) CR7585A (no)
EC (1) ECSP045492A (no)
IL (1) IL165210A0 (no)
MX (1) MXPA04011634A (no)
NI (1) NI200400065A (no)
NO (1) NO20044954L (no)
NZ (1) NZ537051A (no)
RU (1) RU2355397C2 (no)
SG (1) SG162615A1 (no)
UA (1) UA85374C2 (no)
WO (1) WO2003105834A1 (no)
ZA (1) ZA200409991B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272717A1 (en) * 2004-01-13 2005-12-08 Wyeth Treatment of aromatase inhibitor therapy-related osteoporosis
KR20060134146A (ko) * 2004-04-08 2006-12-27 와이어쓰 선택적 에스트로겐 수용체 모듈레이터로서의 바제독시펜아스코르베이트
US20050227966A1 (en) * 2004-04-08 2005-10-13 Wyeth Bazedoxifene acetate formulations
RU2007132852A (ru) * 2005-03-31 2009-05-10 Вайет (Us) Продукт комбинации о-десметилвенлафаксина и базедоксифена и его применение
WO2007002823A2 (en) * 2005-06-29 2007-01-04 Wyeth Formulations of conjugated estrogens and bazedoxifene
EP1919456A2 (en) * 2005-08-24 2008-05-14 Wyeth a Corporation of the State of Delaware Bazedoxifene acetate formulations and manufacturing process thereof
AU2007325207A1 (en) * 2006-11-29 2008-06-05 Wyeth Estrogen/ serm and estrogen/ progestin bi-layer tablets
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
WO2013182169A1 (en) * 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
KR101940569B1 (ko) * 2017-05-24 2019-01-21 아주대학교산학협력단 바제독시펜 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물
CN112076163B (zh) * 2019-06-14 2023-06-20 四川科伦药物研究院有限公司 一种醋酸巴多昔芬片的药物组合物及其制备方法
CN113244240A (zh) * 2021-05-26 2021-08-13 深圳市人民医院 醋酸巴多昔芬在治疗急性髓系白血病药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
TW303299B (no) * 1993-07-22 1997-04-21 Lilly Co Eli
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
EP0802183B1 (en) * 1996-04-19 2001-10-10 American Home Products Corporation Estrogenic agents
US6583170B1 (en) * 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
WO2002003991A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for increasing nitric oxide synthase activity
WO2002003992A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating prosthesis-related bone degeneration
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis

Also Published As

Publication number Publication date
RU2355397C2 (ru) 2009-05-20
RU2004136316A (ru) 2005-05-10
ZA200409991B (en) 2007-09-26
IL165210A0 (en) 2005-12-18
CA2489098A1 (en) 2003-12-24
KR20050010886A (ko) 2005-01-28
NZ537051A (en) 2007-11-30
ECSP045492A (es) 2005-03-10
WO2003105834A1 (en) 2003-12-24
NI200400065A (es) 2005-08-09
US20040063692A1 (en) 2004-04-01
JP2005531613A (ja) 2005-10-20
CN1658868A (zh) 2005-08-24
AU2003248707A1 (en) 2003-12-31
UA85374C2 (en) 2009-01-26
EP1531807A4 (en) 2007-10-31
SG162615A1 (en) 2010-07-29
EP1531807A1 (en) 2005-05-25
CR7585A (es) 2008-10-03
BR0311774A (pt) 2007-05-08
MXPA04011634A (es) 2005-07-05

Similar Documents

Publication Publication Date Title
CL2008003391A1 (es) Compuestos derivados de pirrolidinas, moduladores de la funcion del receptor de androgeno (divisional de la solicitud 970-03).
NO20044954L (no) Bazedoxifen behandlingsregimer
ATE429226T1 (de) Verwendung von verbindungen, die als selektive opiat-rezeptor-modulatoren wirksam sind
DE60331444D1 (de) 1h-1,2,4- triazol-3- carboxamid derivate als cannabinoid-cb1 receptor liganden
EA200500520A1 (ru) Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов
EA200501430A1 (ru) Лиганды каннабиноидных рецепторов и их применение
ATE388937T1 (de) Agonisten des cannabinoidrezeptors
ATE439357T1 (de) Indolylderivate als liver-x-rezeptormodulatoren
DE60336314D1 (de) Substituierte indole
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
NO20053101L (no) Kimaere og humaniserte antistoffer motalfa-5beta-1 integrin som modulerer angiogenese.
NO20051042L (no) Pyrimidylsulfonamidderivater som kemokinreseptormodulatorer
NO994850L (no) Farmakologiske midler
EP1906968A4 (en) NEW SCHEMES FOR ORAL MONOPHASIC CONTRAZEPTIVA
DK1636221T3 (da) 3-Heterocyclyl-azetidin-forbindelser, som er nytte som NK1/NK2 receptorantagonister
NO20034130D0 (no) Benzimidazolderivater som modulerer kjemokinreseptor
DE60316180D1 (de) Aminoalkoxyindol-derivate als 5-ht6-rezeptorliganden zur bekämpfung von zns-krankheiten
MA25264A1 (fr) 3-[benz(ox/thi)azol-7-yl)-1h-pyrimidine-2,4-diones
DK1725232T3 (da) (Indol-3-yl)-heterocykliske derivater som agonister for cannabinoid-CB1-receptoren
CY1110441T1 (el) Μεθοδος για τον καθορισμο μιας μη-ανοσοσφαιρινικης πρωτεϊνης η οποια περιλαμβανει μια ανοσοσφαιρινη-ομοια (ig-ομοια) περιοχη
AR048394A1 (es) Tratamiento de la osteoporosis relacionada con la terapia de inhibidor de aromatasa
ATE273389T1 (de) Rezeptor des y-y5 neuropeptids
WO2006047269A3 (en) Pharmaceutical compositions
DE602006018910D1 (de) 1-(imidazolin-2-yl)amino-1,2-diphenylethan-verbindungen zur bekämpfung von tierpestkrankheiten
NO20052012L (no) Indoler nyttige for behadling av androgen-reseptor relaterte sykdommer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application